Physician profile
Lee Berman
NPI 1508271867
$3,255.45
in general payments reported to CMS, 2019-2025
23 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $38.41 · 2021: $91.84 · 2022: $235 · 2023: $715 · 2024: $934 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,738.95 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $520.54 | 2022-2025 | Sunosi, Auvelity |
| Abbvie INC. | $453.21 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $270.41 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $269.75 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $268.96 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Harmony Biosciences LLC | $195.78 | 2023-2025 | Wakix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.22 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $151.08 | 2019-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $133.46 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $107.08 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $102.96 | 2022-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $85.02 | 2022-2025 | Nuplazid |
| Allergan, INC. | $75.55 | 2019-2020 | |
| Livanova USA, INC. | $74.56 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Indivior INC. | $67.53 | 2022-2024 | Perseris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $65.04 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $51.19 | 2019-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $43.00 | 2023-2025 | Fanapt, Hetlioz |
| Lilly USA, LLC | $38.80 | 2024-2025 | Amyvid, Kisunla |
| Ironshore Pharmaceuticals INC. | $34.81 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $28.87 | 2022-2023 | Trintellix |
| Collegium Pharmaceutical, INC. | $19.79 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $14.84 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.